Werkgroep Cardiologische centra Nederland

PACIFIC-AF (Recruiting)

Randomized, active comparator-controlled, double-blind, double-dummy, parallel group, dose-finding Phase 2 study to compare the safety of the oral FXIa inhibitor BAY 2433334 to a NOAC (apixaban) in patients with atrial fibrillation (AF)
Medicine
Oral FXIa inhibitor BAY 2433334
Population
Arrhythmia
Phase
II
Starting year
2019
More information
Clinicaltrials.gov

Director of Study

dr. M.E.W. Hemels (Cardioloog)
Arnhem, Rijnstate Ziekenhuis